Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 12;22(1):1298.
doi: 10.1186/s12885-022-10408-7.

Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases

S Voutilainen  1 , P Heikkilä  2 , J Bartkova  3   4 , H Nevanlinna  5 , C Blomqvist  6 , J Bartek  3   4 , J Mattson  6
Affiliations

Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases

S Voutilainen et al. BMC Cancer. .

Abstract

Background: Metaplastic breast cancer (MpBC) is an aggressive subtype of breast carcinoma that is often resistant to conventional chemotherapy. Therefore, novel treatment strategies are urgently needed. Immune check point inhibitors have shown activity in programmed death-ligand 1 (PD-L1) - positive metastatic triple negative breast carcinoma (TNBC), which raises the possibility that immunotherapy may also be effective in MpBC as most of the MpBCs are triple negative. The aim of the present study was to assess genomic instability and immunogenicity in tumor specimens of patients with MpBC.

Methods: A total of 76 patients diagnosed with MpBC over a 15-year period were included in the study. We performed immunohistochemical analyses for tumor cell PD-L1, immune cell PD-L1 and p53 on tissue microarrays (TMAs), analyzed stromal and intratumoral tumor infiltrating lymphocytes (TILs) from hematoxylin and eosin-stained (H&E) slides and scored gamma-H2AX (γH2AX) and phosphorylated-RPA2 (pRPA2) from whole tissue sections. We correlated marker expression with clinicopathologic features and clinical outcome.

Results: All tumors expressed γH2AX and pRPA2 with median expressions of 43% and 44%. P53- (68%), tumor cell PD-L1- (59%) and immune cell PD-L1-positivity (62%) were common in MpBCs. Median stromal TIL and intratumoral TIL counts were 5% and 0. The spindle and squamous cell carcinomas expressed the highest levels of PD-L1 and TILs, and carcinoma with mesenchymal differentiation the lowest.

Conclusions: MpBC appears to be an immunogenic cancer with high genomic instability and frequent PD-L1-positivity, implying that check point inhibitors might be effective in MpBC. Expression levels of PD-L1 and TILs varied across different histologic subtypes, suggesting that immunotherapy might be less effective in carcinoma with mesenchymal differentiation.

Keywords: Metaplastic breast cancer; PD-L1; RPA2; TILs; p53; γH2AX.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Representative images of immunohistochemical staining of γH2AX, pRPA2, PD-L1 and TILs. A Representative examples of heterogenous staining patterns for γH2AX (left) and phospho-RPA (right) in breast carcinoma; magnification: 40 × lens. B Representative examples of PD-L1 positive lymphocytes and tumor cells (left) and tumor infiltrating lymphocytes in HE-stained section (right); magnification: 20 × lens
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev. 2019;79:101888. doi: 10.1016/j.ctrv.2019.08.004. - DOI - PubMed
    1. Takala S, Heikkilä P, Nevanlinna H, Blomqvist C, Mattson J. Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease. Breast J. 2019;25(3):418–424. doi: 10.1111/tbj.13234. - DOI - PubMed
    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. doi: 10.1016/S0092-8674(00)81683-9. - DOI - PubMed
    1. Cao D, Xu H, Xu X, Guo T, Ge W. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Oncoimmunology. 2019;8(9):e1629258. doi: 10.1080/2162402X.2019.1629258. - DOI - PMC - PubMed
    1. Lien HC, Lin CW, Mao TL, Kuo SH, Hsiao CH, Huang CS. P53 Overexpression and Mutation in Metaplastic Carcinoma of the Breast: Genetic Evidence for a Monoclonal Origin of both the Carcinomatous and the Heterogeneous Sarcomatous Components. J Pathol. 2004;204(2):131–139. doi: 10.1002/path.1624. - DOI - PubMed

MeSH terms